Assuntos
Síndrome de Cushing , Líquen Escleroso e Atrófico , Líquen Escleroso Vulvar , Humanos , Feminino , Líquen Escleroso e Atrófico/tratamento farmacológico , Síndrome de Cushing/induzido quimicamente , Líquen Escleroso Vulvar/tratamento farmacológico , Esteroides/uso terapêutico , Doença Iatrogênica , Administração TópicaRESUMO
Dermatofibrosarcoma protuberans (DFSP) is rare, comprising (1%-6%) of all sarcomas. The incidence is less than one per million before the age of 20. It is a locally aggressive tumor with a low risk of metastasis. We share our experience in the management of three pediatric patients with complex cases of DFSP in a combined surgical approach involving plastic and dermatologic surgery, using the slow Mohs micrographic surgery technique.
Assuntos
Dermatofibrossarcoma , Sarcoma , Neoplasias Cutâneas , Criança , Dermatofibrossarcoma/cirurgia , Humanos , Cirurgia de Mohs , Recidiva Local de Neoplasia/cirurgia , Neoplasias Cutâneas/cirurgiaRESUMO
We present the case of 60-year-old man with type 2 diabetes who developed blistering after two sequential exposures to linagliptin. Linagliptin is one of the dipeptidyl peptidase 4 (DPP-4) inhibitors, a group of oral hypoglycaemic agents used commonly for the treatment of type 2 diabetes. On the first exposure to linagliptin, he developed blisters on the hands which resolved after stopping the drug. After repeat exposure, he developed two large blisters on the left foot, which burst giving rise to secondary infection, requiring hospital admission for treatment. We discuss the latest research linking DPP-4 inhibitors with adverse skin reactions and the effect of ulcers on the morbidity and mortality of patients with diabetes. This case report highlights skin reactions as an important, rare and lesser known side effect of DPP-4 inhibitors.
